Skip to content

Pain free normal vaginal delivery

Maternal and fetal outcomes in three regimens for intrathecal analgesia in multipara women undergoing normal vaginal delivery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201710002424167
Enrollment
100
Registered
2017-07-13
Start date
2017-08-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth pan free normal vaginal delivery

Interventions

group D
group C

Sponsors

Faculty of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Multipara woman, ASA physical status I or II, in active labor with engaged fetal head, term pregnancy of singleton fetus not in distress (Normal cardiotocography [baseline fetal heart rate between 110 and 160 beats/minute, baseline variability >5 beats/minute, presence of accelerations, and absence of decelerations], minimal cervical dilatation of at least 3 cm with intact membranes, those requiring oxytocin augmentation, cephalic presentation, and uncomplicated pregnancies.

Exclusion criteria

Exclusion criteria: Patients who refuse to participate, preexisting or pregnancy-induced hypertension, obesity, endocrine diseases, diagnosed fetal abnormalities, contra-indications to neuraxial anesthesia, occurrence of wet tap during epidural placement, fade of spinal analgesia & hence need for epidural activation, previous systemic opioid administrations, allergy to study agents, unconscious parturients, patients who are unable to communicate.

Design outcomes

Primary

MeasureTime frame
maternal VAS score;Time for the beginning of analgesia in each group (onset time).;The level of sensory block will be assessed using alcohol swabs on both sides of the body and the maximum level of sensory block ;The time from intrathecal injection to two dermatome sensory regression, sensory regression to S1 dermatome, and motor block regression to Bromage 1 ;Pain at the peak of a contraction ;pain score during the last contraction ;Duration of pain relief defined as the time from spinal injection to the first request for rescue analgesics or when the VAS is >3.and Time to first administration of supplemental analgesics (clinical duration);Highest sensory block to pin prick in the midline ;Motor block as assessed by the modified bromage scale;Fetal heart rate ;Apgar score ;Umbilical arterial blood gases ;neonatal heart rate

Secondary

MeasureTime frame
maternal adverse effects: respiratory depression ¿ Hypotension (and the need of ephedrine supplementation). . Nausea and vomiting, Shivering, Pruritus, respiratory depression, urine retention;Hemodynamic changes (pulse & blood pressure) 5, 10, 15, 20, 30, 60 and 120 minutes after block. Hemodynamic changes (pulse & blood pressure) ;fetal heart rate;maternal sedation state by modified Ramsay sedation score;maternal adverse to effects:nausea, vomiting, pruritis, respiratory depression, Shivering, urine retention, pistdural puncture headache, back pain, neurological damage

Countries

Egypt

Contacts

Public Contactsabry abdallah

lecturer in aneaesthesia and intesnive care

sabryabdallah222@yahoo.com00201012378888

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026